Episode

What is driving the comeback story in biopharma?

Podcast
UBS Global Research Pod Hub
Published
Feb 13, 2026
Duration seconds
911
Processing state
not_requested
Canonical source
https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/mike-dimiter.mp3
Audio
https://www.ubs.com/content/dam/assets/ib/global/podcast/research-podcasts/mike-dimiter.mp3
JSON
/v1/public/podcasts/ubs-global-research-pod-hub-6511142/episodes/what-is-driving-the-comeback-story-in-biopharma
Markdown
/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/ubs-global-research-pod-hub-6511142/episodes/what-is-driving-the-comeback-story-in-biopharma/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/ubs-global-research-pod-hub-6511142/what-is-driving-the-comeback-story-in-biopharma.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

With drug pricing cuts easing, investor interest is returning, driven by fresh innovation, active M&A, and rotation into a long undervalued sector. Dimiter Tassev, UBS Healthcare Advisory Sales Specialist, speaks with Michael Yee, Global Head of Biotechnology Research at UBS investment Bank, about the outlook for US biopharma. *(This information is subject to a disclaimer at the end of this podcast. Please ensure that you listen to the disclaimer and go to www.ubs.com for further information about UBS).